Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.33 |
| ▸ | NPY1R | P25929 | 3/20 | 0.33 |
| ▸ | NPY4R | P50391 | 3/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.30 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22267887 | 0.87 | CASP1 (0.33) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20935177 | 0.86 | NPY5R (0.35) | NPY5RNPY1RNPY4RC3AR1NPY2R | |
| SCHEMBL23353440 | 0.85 | NMT1 (0.39) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20864130 | 0.84 | SIRT2 (0.35) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL22841086 | 0.82 | NPY5R (0.37) | NPY5RNPY1RNPY4RC3AR1NPY2R | |
| SCHEMBL19681474 | 0.82 | NPY5R (0.39) | NPY5RNPY1RNPY4RC3AR1NPY2R | |
| SCHEMBL22100772 | 0.81 | SIRT2 (0.36) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL18911086 | 0.80 | KISS1R (0.34) | NPY5RNPY1RNPY4RC3AR1NPY2R | |
| SCHEMBL20935183 | 0.78 | NPY4R (0.36) | NPY5RNPY1RNPY4RC3AR1NPY2R | |
| SCHEMBL20340671 | 0.78 | SIRT2 (0.36) | NPY5RNPY1RNPY4RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | CD2, CD4, CD22 | NPY5R 3882/4885NPY1R 3926/4885NPY4R 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.